Cogent Biosciences Inc
COGT9.350USD
+1.770+23.35%
收盤 07/07, 16:00（美東）報價延遲15分鐘
1.06B總市值
虧損本益比TTM
關於 Cogent Biosciences Inc 公司
Cogent Biosciences, Inc. 是一家生物技術公司。該公司專注於開發針對基因定義疾病的精準療法。該公司的臨牀項目貝祖卡斯替尼是一種選擇性酪氨酸激酶抑制劑，旨在有效抑制 KIT D816V 突變以及 KIT 外顯子 17 中的其他突變。KIT D816V 負責驅動系統性肥大細胞增多症，這是一種由肥大細胞不受控制的增殖引起的嚴重疾病。除了貝祖卡斯替尼，該公司還在開發一系列新型靶向療法，以幫助患者對抗最初針對 FGFR2、ErbB2 和 PI3Kα 突變的嚴重基因驅動疾病。SUMMIT 是其針對非 AdvSM 患者的隨機、全球、多中心、雙盲、安慰劑對照、多部分 II 期臨牀試驗。APEX 是一項開放標籤、全球、多中心研究，評估貝祖卡斯替尼的安全性、有效性、藥代動力學和藥效學特徵。
公司簡介
公司代碼COGT
公司名稱Cogent Biosciences Inc
上市日期Mar 29, 2018
成立日期2014
CEOMr. Andrew Robbins
員工數量205
證券類型Ordinary Share
年結日Mar 29
公司地址275 Wyman Street
城市WALTHAM
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02451
電話16179455576
網址https://www.cogentbio.com/
公司代碼COGT
上市日期Mar 29, 2018
成立日期2014
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Cole Pinnow
Mr. Cole Pinnow
Chief Commercial Officer
Chief Commercial Officer
45.85K
+3.15%
Mr. Evan D. Kearns, J.D.
Mr. Evan D. Kearns, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Matthew E. Ros
Mr. Matthew E. Ros
Independent Director
Independent Director
--
--
Dr. Karen Jean Ferrante, M.D.
Dr. Karen Jean Ferrante, M.D.
Independent Director
Independent Director
--
--
Mr. Todd E. Shegog
Mr. Todd E. Shegog
Independent Director
Independent Director
--
--
Dr. John Robinson, Ph.D.
Dr. John Robinson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John L. Green
Mr. John L. Green
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Arlene M. Morris
Ms. Arlene M. Morris
Independent Director
Independent Director
--
--
Mr. Andrew Robbins
Mr. Andrew Robbins
Chief Executive Officer, President, Director
Chief Executive Officer, President, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Cole Pinnow
Mr. Cole Pinnow
Chief Commercial Officer
Chief Commercial Officer
45.85K
+3.15%
Mr. Evan D. Kearns, J.D.
Mr. Evan D. Kearns, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Matthew E. Ros
Mr. Matthew E. Ros
Independent Director
Independent Director
--
--
Dr. Karen Jean Ferrante, M.D.
Dr. Karen Jean Ferrante, M.D.
Independent Director
Independent Director
--
--
Mr. Todd E. Shegog
Mr. Todd E. Shegog
Independent Director
Independent Director
--
--
Dr. John Robinson, Ph.D.
Dr. John Robinson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
收入明細
FY2021
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.45%
Kynam Capital Management LP
8.00%
Paradigm BioCapital Advisors LP
7.87%
Commodore Capital LP
7.81%
BlackRock Institutional Trust Company, N.A.
6.57%
Other
57.30%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.45%
Kynam Capital Management LP
8.00%
Paradigm BioCapital Advisors LP
7.87%
Commodore Capital LP
7.81%
BlackRock Institutional Trust Company, N.A.
6.57%
Other
57.30%
股東類型
持股股東
佔比
Hedge Fund
47.38%
Investment Advisor
34.96%
Investment Advisor/Hedge Fund
22.22%
Venture Capital
8.74%
Research Firm
4.11%
Private Equity
0.82%
Pension Fund
0.28%
Bank and Trust
0.21%
Corporation
0.12%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
361
135.28M
118.82%
-6.42M
2025Q1
370
134.69M
118.30%
-7.69M
2024Q4
356
122.59M
107.82%
-16.59M
2024Q3
355
122.94M
112.32%
-17.94M
2024Q2
346
122.41M
127.95%
-6.37M
2024Q1
333
110.27M
115.27%
-1.77M
2023Q4
312
93.09M
108.04%
-6.98M
2023Q3
299
95.11M
113.69%
-5.31M
2023Q2
295
93.33M
133.52%
+4.32M
2023Q1
287
79.36M
115.42%
-7.30M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
14.17M
12.45%
+198.56K
+1.42%
Mar 31, 2025
Kynam Capital Management LP
9.11M
8%
--
--
Mar 31, 2025
Paradigm BioCapital Advisors LP
8.96M
7.87%
+3.40M
+61.22%
Mar 31, 2025
Commodore Capital LP
8.89M
7.81%
+2.01M
+29.23%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.48M
6.57%
-85.44K
-1.13%
Mar 31, 2025
TCG Crossover Management, LLC
6.96M
6.12%
--
--
Apr 14, 2025
VR Adviser, LLC
6.38M
5.6%
+691.51K
+12.16%
Apr 14, 2025
Fairmount Funds Management LLC
6.23M
5.47%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
6.04M
5.31%
-75.04K
-1.23%
Mar 31, 2025
Point72 Asset Management, L.P.
5.30M
4.65%
-51.76K
-0.97%
Mar 31, 2025
查看更多
持股ETF
更新時間: 7月6日 週日
更新時間: 7月6日 週日
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
Tema Oncology ETF
0.92%
SPDR S&P Biotech ETF
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.07%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.93%
Tema Oncology ETF
佔比0.92%
SPDR S&P Biotech ETF
佔比0.17%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.13%
iShares Micro-Cap ETF
佔比0.11%
ProShares Ultra Nasdaq Biotechnology
佔比0.09%
Invesco Nasdaq Biotechnology ETF
佔比0.07%
Fidelity Enhanced Small Cap ETF
佔比0.07%
iShares Biotechnology ETF
佔比0.05%
iShares Russell 2000 Growth ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
公告日期
類型
比率
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
Nov 06, 2020
Merger
4<1
